Platelets in cancer: From basic research to therapeutic implications

Hamostaseologie

Volumn 35, Issue 4, 2015, Pages 325-336

  Mammadova Bach, E ^a,b,c,d   Mangin, P ^a,b,c,d   Lanza, F ^a,b,c,d   Gachet, Christian ^a,b,c,d  

^a INSERM   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d Fédération de Médecine Translationnelle de Strasbourg   (France)

Author keywords

Anti platelet agents; Cancer; Platelet physiology; Tumor metastasis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA3 INTEGRIN;

ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; BASIC RESEARCH; CANCER GROWTH; CANCER INHIBITION; CELL INTERACTION; CLINICAL TRIAL (TOPIC); DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOSURVEILLANCE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE; THROMBOSIS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; EVIDENCE BASED MEDICINE; HOMEOSTASIS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; TRANSLATIONAL RESEARCH; TRENDS;

ANIMALS; BLOOD PLATELETS; EVIDENCE-BASED MEDICINE; HOMEOSTASIS; HUMANS; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84964768919     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/hamo-14-11-0065     Document Type: Review

References (125)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
3. Olson OC, Joyce JA. Microenvironment-mediated resistance to anticancer therapies. Cell Res 2013; 23: 179-181.
4. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-1729.
5. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410.
6. Tranum BL, Haut A. Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 1974; 84: 615-619.
7. Khorana AA. Cancer and coagulation. Am J Hematol 2012; 87 (Suppl 1): S82-S87.
8. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93: 327-358.
9. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl 1): S13-S33.
10. Bertozzi CC, Hess PR, Kahn ML. Platelets: covert regulators of lymphatic development. Arterioscler Thromb Vasc Biol 2010; 30: 2368-2371.
11. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nature reviews. Immunology 2011; 11: 264-274.
12. Stegner D, Dutting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res 2014; 133 (Suppl 2): S149-S157.
13. Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hämostaseologie 2014; 34: 54-62.
14. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost 2014; 40: 296-305.
15. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nature reviews. Cancer 2011; 11: 123-134.
16. Di Nisio M, Porreca E, Otten HM, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. The Cochrane database of systematic reviews 2014; 8: CD008500.
17. Stone RL et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2013; 366: 610-618.
18. Sasaki Y et al. Production of thrombopoietin by human carcinomas and its novel isoforms. Blood 1999; 94: 1952-1960.
19. Rank A et al. Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Res 2012; 32: 2009-2014.
20. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143: 819-826.
21. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res 2008; 28(5B): 2997-3006.
22. Dang Q, Liu J, Li J, Sun Y. Podoplanin: a novel regulator of tumor invasion and metastasis. Med Oncol 2014; 31: 24.
23. Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012; 129 (Suppl 1): S30-S37.
24. Takagi S et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PloS one 2013; 8: e73609.
25. Han X, Guo B, Li Y, Zhu B. Tissue factor in tumor microenvironment: a systematic review. J Hematol Oncol 2014; 7: 54.
26. Demers M et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 2012; 109: 13076-13081.
27. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
28. Italiano JE Jr et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
29. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011; 118: 1359-1369.
30. Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 2010; 21: 85-93.
31. Kamykowski J, Carlton P, Sehgal S, Storrie B. Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet alpha-granules. Blood 2011; 118: 1370-1373.
32. Jonnalagadda D, Izu LT, Whiteheart SW. Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood 2012; 120: 5209-5216.
33. Klement GL et al. Platelets actively sequester angiogenesis regulators. Blood 2009; 113: 2835-2842.
34. Feng W et al. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. Blood 2011; 117: 3893-3902.
35. Kuznetsov HS et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer discovery 2012; 2: 1150-1165.
36. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998; 125: 1252-1257.
37. Qi J, Goralnick S, Kreutzer DL. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood 1997; 90: 3595-3602.
38. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 2004; 124: 376-384.
39. Janowska-Wieczorek A et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International journal of cancer. J Int Cancer 2005; 113: 752-760.
40. Brill A, Dashevsky O, Rivo J et al. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005; 67: 30-38.
41. Helley D et al. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxelbased chemotherapy. Eur Urol 2009; 56: 479-484.
42. Kim HK et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003; 39: 184-191.
43. Twombly R. Avastin's uncertain future in breast cancer treatment. J Natl Cancer Inst 2011; 103: 458-460.
44. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature reviews. Cancer 2003; 3: 453-458.
45. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46-52.
46. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81: 1012-1019.
47. Camerer E et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401.
48. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discovery 2012; 2: 1091-1099.
49. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
50. Placke T et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res 2012; 72: 440-448.
51. Palumbo JS et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.
52. Skov Madsen P, Hokland P, Hokland M. Secretory products from thrombin-stimulated human platelets exert an inhibitory effect on NK-cytotoxic activity. Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology 1986; 94: 193-200.
53. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009; 69: 7775-7783.
54. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGFbeta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335-7340.
55. Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res 2012; 72: 4662-4671.
56. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 2014; 3: 17.
57. Dovizio M et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol 2013; 84: 25-40.
58. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer cell 2011; 20: 576-590.
59. Alves CS, Burdick MM, Thomas SN et al. The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. Am J Physiol Cell Physiol 2008; 294: C907-916.
60. Qi CL et al. P-selectin-mediated platelet adhesion promotes the metastasis of murine melanoma cells. PLoS One 2014; 9: e91320.
61. Coupland LA, Parish CR. Platelets, selectins, and the control of tumor metastasis. Semin Oncol 2014; 41: 422-434.
62. McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 2000; 96: 1789-1797.
63. Zhang C et al. Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo. International journal of cancer. J Int Cancer 2009; 125: 2058-2065.
64. Bakewell SJ et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003; 100: 14205-14210.
65. Boucharaba A et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-1725.
66. Pilch J, Habermann R, Felding-Habermann B. Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions. J Biol Chem 2002; 277: 21930-21938.
67. Morimoto K et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 2008; 27: 264-273.
68. Leblanc R et al. Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood 2014; 124: 3141-3150.
69. Jain S et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA 2007; 104: 9024-9028.
70. Erpenbeck L, Nieswandt B, Schon M et al. Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. J Invest Dermatol 2010; 130: 576-586.
71. Schumacher D, Strilic B, Sivaraj KK et al. Plateletderived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013; 24: 130-137.
72. Guerrero JA et al. Gray platelet syndrome: Pro-inflammatory megakaryocytes and alpha-granule loss cause myelofibrosis and confer resistance to cancer metastasis in mice. Blood 2014; 124: 3624-3635.
73. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 2009; 7: 1713-1717.
74. Zahid M et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost 2012; 10: 2418-2427.
75. Schaphorst KL et al. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol 2003; 285: L258-L267.
76. Yin F, Watsky MA. LPA and S1P increase corneal epithelial and endothelial cell transcellular resistance. Invest Ophthalmol Vis Sci 2005; 46: 1927-1933.
77. Cote F, Fligny C, Fromes Y et al. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004; 10: 232-238.
78. Skolnik G, Bagge U, Blomqvist G et al. The role of calcium channels and serotonin (5-HT2) receptors for tumour cell lodgement in the liver. Clin Exp Metastasis 1989; 7: 169-174.
79. Kuna P et al. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992; 149: 636-642.
80. Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol 2010; 161: 755-767.
81. Cools-Lartigue J et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 2013; 123: 3446-3458.
82. Yu LX et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nature Commun 2014; 5: 5256.
83. Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA 2014; 111: E3053-E3061.
84. Oskarsson T et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature Med 2011; 17: 867-874.
85. O'Connell JT et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA 2011; 108: 16002-16007.
86. SchaffM et al. Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol 2011; 31: 117-124.
87. Brellier F et al. Tenascin-C triggers fibrin accumulation by downregulation of tissue plasminogen activator. FEBS letters 2011; 585: 913-920.
88. Patrono C, Baigent C, Hirsh J et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133 (6 Suppl): 199S-233S.
89. Gasic GJ, Gasic TB, Galanti N et al. Platelettumor-cell interactions in mice. The role of pla-telets in the spread of malignant disease. Int J Cancer 1973; 11: 704-718.
90. Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer 2014; 111: 61-67.
91. Chulada PC, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-4708.
92. Sciulli MG et al. Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 79-83.
93. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613.
94. Rothwell PM et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601.
95. Reimers MS et al. Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. J Am Geriatr Soc 2012; 60: 2232-2236.
96. Zhang S et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer 2014; 110: 2378-2388.
97. Cuzick J, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011; 12: 496-503.
98. Stark LA et al. Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 2007; 28: 968-976.
99. Bos CL et al. Effect of aspirin on the Wnt/betacatenin pathway is mediated via protein phosphatase 2A. Oncogene 2006; 25: 6447-6456.
100. Din FV et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 2012; 142: 1504-1515.
101. Neugut AI. Aspirin as adjuvant therapy for stage III colon cancer: standard of care? JAMA Int Med 2014; 174: 739-741.
102. Seshasai SR et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Int Med 2013; 172: 209-216.
103. Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nature reviews. Gastroenterol Hepatol 2011; 8: 385-394.
104. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-638.
105. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277-300.
106. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.
107. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121: 171-179.
108. Berger JS et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009; 120: 2337-2344.
109. Bastida E, Escolar G, Almirall L, Ordinas A. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb Haemost 1986; 55: 333-337.
110. Mezouar S, Darbousset R, Dignat-George F et al. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer 2015; 136: 462-475.
111. Gebremeskel S, LeVatte T, Liwski RS et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer 2015; 136: 234-240.
112. Wang Y et al. Platelet P2Y12 is involved in murine pulmonary metastasis. PloS One 2013; 8: e80780.
113. Rohr S et al. Quantitative image analysis of angiogenesis in rats implanted with a fibrin gel chamber. Nouvelle Revue Francaise d'Hematologie 1992; 34: 287-294.
114. Klein-Soyer C et al. Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts. Biol Cell 1997; 89: 295-307.
115. Mah-Becherel MC et al. Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. Br J Cancer 2002; 86: 803-810.
116. Gachet C. P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal 2012; 8: 609-619.
117. Su X et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest 2012; 122: 3579-3592.
118. Nanau RM, Delzor F, Neuman MG. Efficacy and safety of prasugrel in acute coronary syndrome patients. Clin Biochem 2014; 47: 516-528.
119. Buckley LA et al. Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent. Int J Toxicol 2012; 31: 317-325.
120. Bledzka K, Smyth SS, Plow EF. Integrin alphaIIbbeta3: from discovery to efficacious therapeutic target. Circ Res 2013; 112: 1189-1200.
121. Timar J et al. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology 2005; 69: 185-201.
122. Zhang W et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood 2013; 120: 2889-2898.
123. Stoll P et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007; 27: 1206-1212.
124. Sarkar S, Alam MA, Shaw J, Dasgupta AK. Drug delivery using platelet cancer cell interaction. Pharm Res 2013; 30: 2785-2794.
125. Tanaka K et al. In vivo optical imaging of cancer metastasis using multiphoton microscopy: a short review. Am J Transl Res 2014; 6: 179-187.